ClinicalTrials.gg
CompletedNCT01208207Updated Jun 18, 2024Results posted

A Two-Part 26-Week Study of Etoricoxib as Treatment for Ankylosing Spondylitis (AS) (MK-0663-108)

A Phase 3 interventional study of Part I - etoricoxib 60 mg and Part I - etoricoxib 90 mg in Spondylitis, Ankylosing, sponsored by Organon and Co. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,015
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of the study is to evaluate the efficacy and tolerability of two doses of etoricoxib compared to naproxen in the treatment of ankylosing spondylitis (AS). The primary objectives are to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg or 60 mg compared to naproxen; and to evaluate the improvement in Spinal Pain Intensity over 6 weeks of treatment with etoricoxib 90 mg compared with etoricoxib 60 mg. Additionally the added benefit of increasing the dose of etoricoxib from 60 mg to 90 mg will be assessed in the second part of the study. The primary hypothesis is that the improvement in Spinal Pain Intensity visual analog scale (VAS) as measured by the time-weighted average (TWA) change from baseline over 6 weeks of treatment in Part I for etoricoxib 90 mg or 60 mg once daily is not inferior to naproxen 1000 mg.

02

Conditions studied

  • Spondylitis, Ankylosing
03

In context

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

This study's enrollment of 1,015 is above the median of 88 across 303 interventional studies indexed under Spondylitis, Ankylosing.

Browse Spondylitis, Ankylosing studies →

Lead sponsor

Organon and Co is the lead sponsor of 505 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 18 (78%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a definite diagnosis of Ankylosing Spondylitis (AS) per Modified New York Criteria made at least 6 months prior to screening
  • Has a history of positive therapeutic benefit with non-steroidal anti-inflammatory drugs (NSAIDs) and regular use of NSAIDS for past 30 days
  • Has a score on Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Question 2 at screening visit that is \<77 mm
  • Must demonstrate sufficient "flare" or worsening of AS pain
  • Is in general good health (other than AS)
  • Has had approved non-study antirheumatic therapy that has been at stable dosing AND is not anticipated to undergo a change within the first 6 weeks of the protocol

Exclusion criteria

Exclusion Criteria:

  • Has inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis, crystal-induced arthritis, spondyloarthropathy, diffuse idiopathic skeletal hyperostosis [DISH]), polymyalgia rheumatica, a history of septic arthritis or intra-articular fracture of the study joint, Wilson's disease, hemachromatosis, ochronosis, or primary osteochondromatosis
  • Has acute peripheral articular disease (onset within 4 weeks prior to screening) of an active (painful or swollen) peripheral arthritis
  • Has a history of gastric or biliary surgery, or small intestine surgery that causes clinical malabsorption
  • Has had an active peptic (gastric or duodenal) ulcer or history of inflammatory bowel disease
  • Has undergone coronary artery bypass graft surgery (CABG), angioplasty, or has a cerebrovascular accident or within the past 6 months or has active ischemic heart disease, cerebrovascular disease, or peripheral vascular disease
  • Has Class II-IV congestive heart failure
  • Has uncontrolled hypertension
  • Has a history of neoplastic disease, except adequately treated basal cell carcinoma or carcinoma in situ of the cervix, or that have been successfully treated ≥ 5 years prior to screening
  • Has history of leukemia, lymphoma, malignant melanoma, and myeloproliferative disease
  • Allergy to etoricoxib or naproxen, or history of a significant clinical or laboratory adverse experience associated with etoricoxib or naproxen
  • Has a history or family history of an inherited or acquired bleeding disorder
  • Is considered morbidly obese and demonstrates significant health problems stemming from obesity, which would confound study participation or interpretation of study results
  • Is pregnant, breast-feeding, or expecting to conceive during the study
  • Has a clinical diagnosis of hepatic insufficiency defined as score ≥ 5
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,015 participants (actual)

Study arms

  • Experimental
    etoricoxib 60 mg/etoricoxib 60 mg

    The etoricoxib 60 mg/etoricoxib 60 mg treatment sequence will receive etoricoxib 60 mg in Part I and Part II

    Drug: Part I - etoricoxib 60 mg · Drug: Part I - Placebo to naproxen 500 mg · Drug: Part II- etoricoxib 60 mg · Drug: Part I - Placebo to etoricoxib 90 mg · Drug: Part II - Placebo to etoricoxib 90 mg · Drug: Part II- Placebo to naproxen 500 mg

  • Experimental
    etoricoxib 60 mg/etoricoxib 90 mg

    The etoricoxib 60 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 60 mg in Part I and etoricoxib 90 mg in Part II

    Drug: Part I - etoricoxib 60 mg · Drug: Part I - Placebo to naproxen 500 mg · Drug: Part II- etoricoxib 90 mg · Drug: Part I - Placebo to etoricoxib 90 mg · Drug: Part II- Placebo to etoricoxib 60 mg · Drug: Part II- Placebo to naproxen 500 mg

  • Experimental
    etoricoxib 90 mg/etoricoxib 90 mg

    The etoricoxib 90 mg/etoricoxib 90 mg treatment sequence will receive etoricoxib 90 mg in Part I and Part II

    Drug: Part I - etoricoxib 90 mg · Drug: Part I - Placebo to naproxen 500 mg · Drug: Part II- etoricoxib 90 mg · Drug: Part I - Placebo to etoricoxib 60 mg · Drug: Part II- Placebo to etoricoxib 60 mg · Drug: Part II- Placebo to naproxen 500 mg

  • Active comparator
    naproxen 1000 mg/naproxen 1000 mg

    The naproxen 1000 mg/naproxen 1000 mg treatment sequence will receive naproxen 1000 mg in Part I and Part II

    Drug: Part I- naproxen 1000 mg · Drug: Part II- naproxen 1000 mg · Drug: Part I - Placebo to etoricoxib 60 mg · Drug: Part I - Placebo to etoricoxib 90 mg · Drug: Part II- Placebo to etoricoxib 60 mg · Drug: Part II - Placebo to etoricoxib 90 mg

Interventions

  • etoricoxib 60 mg oral tablet once daily for 6 weeks

    Also known as: MK-0663

  • etoricoxib 90 mg oral tablet once daily for 6 weeks

    Also known as: Mk-0663

  • DrugPart I- naproxen 1000 mg

    naproxen 500 mg oral tablet twice daily for 6 weeks

  • DrugPart I - Placebo to naproxen 500 mg

    Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks

  • etoricoxib 60 mg oral tablet once daily for 20 weeks

    Also known as: MK-0663

  • etoricoxib 90 mg oral tablet once daily for 20 weeks

    Also known as: MK-0663

  • DrugPart II- naproxen 1000 mg

    naproxen 500 mg oral tablet twice daily for 20 weeks

  • DrugPart I - Placebo to etoricoxib 60 mg

    Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.

  • DrugPart I - Placebo to etoricoxib 90 mg

    Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.

  • DrugPart II- Placebo to etoricoxib 60 mg

    Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.

  • DrugPart II - Placebo to etoricoxib 90 mg

    Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.

  • DrugPart II- Placebo to naproxen 500 mg

    Placebo to naproxen 500 mg orally twice daily for 20 weeks.

06

What researchers measure

Primary outcomes

  1. Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen

    Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Baseline and up to Week 6

  2. Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen

    Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Baseline and up to Week 6

  3. Number of Participants Discontinuing Study Treatment Due to an Adverse Event

    Time frame: Up to 26 weeks

Secondary outcomes

  1. Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg

    Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

    Time frame: Baseline and up to Week 6

  2. Average Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I)

    Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. Average change from Week 6 in Spinal Pain Intensity (VAS) over Weeks 10 and 12 is calculated as the average Spinal pain Intensity (VAS) value over Weeks 10 and 12 minus the Spinal Pain Intensity (VAS) at Week 6.

    Time frame: Week 6 to Week 10 and Week 12

07

Results

Posted Jul 2, 2015

Participant flow

Part I
Participant flow — Part I
MilestoneEtoricoxib 60 mg (Part I)Etoricoxib 90 mg (Part I)Naproxen 1000 mg (Part I)Etoricoxib 60 mg / 60 mg (Part II)Etoricoxib 60 mg / 90 mg (Part II)Etoricoxib 90 mg / 90 mg (Part II)Naproxen 1000 mg (Part II)
Started7021561570000
Completed6321451420000
Not completed7011150000
Withdrew: Adverse event19260000
Withdrew: Lack of efficacy21320000
Withdrew: Lost to follow-up6100000
Withdrew: Non-compliance with study drug1010000
Withdrew: Physician decision0100000
Withdrew: Progressive disease1000000
Withdrew: Protocol violation8020000
Withdrew: Withdrawal by subject14440000
Part II
Participant flow — Part II
MilestoneEtoricoxib 60 mg (Part I)Etoricoxib 90 mg (Part I)Naproxen 1000 mg (Part I)Etoricoxib 60 mg / 60 mg (Part II)Etoricoxib 60 mg / 90 mg (Part II)Etoricoxib 90 mg / 90 mg (Part II)Naproxen 1000 mg (Part II)
Started000314318145142
Completed000282295129131
Not completed00032231611
Withdrew: Withdrawal by subject00010935
Withdrew: Adverse event0005942
Withdrew: Lack of efficacy0006433
Withdrew: Lost to follow-up0004021
Withdrew: Non-compliance with study drug0004110
Withdrew: Physician decision0001020
Withdrew: Protocol violation0001000
Withdrew: Technical problems0001010

Outcome measures

PrimaryTime-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen

Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Baseline and up to Week 6
Reported as:
Least squares mean · mm VAS
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen
mm VASEtoricoxib 90 mgNaproxen 1000 mg
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Naproxen-31.23 (-34.70 to -27.76)-30.59 (-34.07 to -27.10)
Statistical analysis
  • Etoricoxib 90 mg vs Naproxen 1000 mg · ANCOVA · Difference in least squares mean: -0.64 · 95% CI -5.47 to 4.19
PrimaryTime-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen

Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Baseline and up to Week 6
Reported as:
Least squares mean · mm VAS
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen
mm VASEtoricoxib 60 mgNaproxen 1000 mg
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 60 mg vs. Naproxen-29.00 (-30.69 to -27.31)-30.59 (-34.07 to -27.10)
Statistical analysis
  • Etoricoxib 60 mg vs Naproxen 1000 mg · ANCOVA · Difference in least squares mean: 1.59 · 95% CI -2.19 to 5.37
SecondaryTime-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg

Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. The time-weighted average change is calculated by taking the time between adjacent observations divided by the time from the randomization visit to the last observation in the period of interest, and using it as the weight for computation of the average.

Time frame:
Baseline and up to Week 6
Reported as:
Least squares mean · mm VAS
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg
mm VASEtoricoxib 90 mgEtoricoxib 60 mg
Time-Weighted Average Change From Baseline in the Spinal Pain Intensity in Study Part 1: Etoricoxib 90 mg vs. Etoricoxib 60 mg-30.51 (-33.87 to -27.15)-28.94 (-30.58 to -27.29)
Statistical analysis
  • Etoricoxib 90 mg vs Etoricoxib 60 mg · ANCOVA · p = 0.396 · Difference in least squares mean: -1.58 · 80% CI -3.96 to 0.81
SecondaryAverage Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I)

Spinal Pain Intensity is measured using a visual analog scale (VAS) from 0-100 mm with a lower value representing a better response. Average change from Week 6 in Spinal Pain Intensity (VAS) over Weeks 10 and 12 is calculated as the average Spinal pain Intensity (VAS) value over Weeks 10 and 12 minus the Spinal Pain Intensity (VAS) at Week 6.

Time frame:
Week 6 to Week 10 and Week 12
Reported as:
Least squares mean · mm VAS
Average Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I)
mm VASEtoricoxib 60 mg/ 90 mgEtoricoxib 60 mg / 60 mg
Average Change From Week 6 in the Spinal Pain Intensity Over Weeks 10 and 12 in Study Part 2: Etoricoxib 60/90 mg vs. Etoricoxib 60mg (Non-responders From Part I)-9.97 (-12.42 to -7.51)-7.26 (-9.73 to -4.80)
Statistical analysis
  • Etoricoxib 60 mg/ 90 mg vs Etoricoxib 60 mg / 60 mg · ANCOVA · p = 0.112 · Difference in least squares mean: -2.70 · 80% CI -4.88 to -0.52
PrimaryNumber of Participants Discontinuing Study Treatment Due to an Adverse Event
Time frame:
Up to 26 weeks
Reported as:
Number · Participants
Number of Participants Discontinuing Study Treatment Due to an Adverse Event
ParticipantsEtoricoxib 60 mg (Part I)Etoricoxib 90 mg (Part I)Naproxen 1000 mg (Part I)Etoricoxib 60 mg / 60 mg (Part II)Etoricoxib 60 mg / 90 mg (Part II)Etoricoxib 90 mg / 90 mg (Part II)Naproxen 1000 mg (Part II)
Number of Participants Discontinuing Study Treatment Due to an Adverse Event22263942

Adverse events

Collected over Up to Week 30 (including up to 28 days after last dose of study drug). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Etoricoxib 60 mg / Etoricoxib 60 mg—1/313 (0.3%)55/313 (17.6%)
Etoricoxib 60 mg / Etoricoxib 90 mg—7/319 (2.2%)50/319 (15.7%)
Etoricoxib 90 mg / Etoricoxib 90 mg—6/145 (4.1%)24/145 (16.6%)
Naproxen 1000 mg / Naproxen 1000 mg—2/142 (1.4%)25/142 (17.6%)
Etoricoxib 60 mg—5/70 (7.1%)18/70 (25.7%)
Etoricoxib 90 mg—0/10 (0%)6/10 (60%)
Naproxen 1000 mg—0/14 (0%)9/14 (64.3%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventEtoricoxib 60 mg / Etoricoxib 60 mgEtoricoxib 60 mg / Etoricoxib 90 mgEtoricoxib 90 mg / Etoricoxib 90 mgNaproxen 1000 mg / Naproxen 1000 mgEtoricoxib 60 mgEtoricoxib 90 mgNaproxen 1000 mg
Ankylosing spondylitisMusculoskeletal and connective tissue disorders0/3131/3190/1450/1421/700/100/14
Hip fractureInjury, poisoning and procedural complications0/3130/3190/1450/1421/700/100/14
Cerebral infarctionNervous system disorders0/3130/3190/1450/1421/700/100/14
Cerebrovascular accidentNervous system disorders0/3130/3190/1450/1421/700/100/14
HeadacheNervous system disorders0/3130/3190/1450/1421/700/100/14
ProstatitisReproductive system and breast disorders0/3130/3190/1450/1421/700/100/14
Hypertensive crisisVascular disorders0/3130/3190/1450/1421/700/100/14
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/3130/3192/1450/1420/700/100/14
Non-cardiac chest painGeneral disorders0/3130/3190/1451/1420/700/100/14
AbscessInfections and infestations0/3130/3190/1451/1420/700/100/14
Most frequent other events
Showing 10 of 24
Most frequent other events
EventEtoricoxib 60 mg / Etoricoxib 60 mgEtoricoxib 60 mg / Etoricoxib 90 mgEtoricoxib 90 mg / Etoricoxib 90 mgNaproxen 1000 mg / Naproxen 1000 mgEtoricoxib 60 mgEtoricoxib 90 mgNaproxen 1000 mg
HypertensionVascular disorders18/31315/3198/1458/1424/700/102/14
NauseaGastrointestinal disorders5/3133/3193/1451/1424/700/102/14
HeadacheNervous system disorders10/31313/3199/1455/1424/701/101/14
PalpitationsCardiac disorders2/3130/3190/1450/1420/701/101/14
Abdominal painGastrointestinal disorders3/3133/3190/1451/1421/701/100/14
DiarrhoeaGastrointestinal disorders7/3138/3192/1454/1424/701/101/14
Blood pressure increasedInvestigations9/3137/3190/1450/1421/701/100/14
DysgeusiaNervous system disorders0/3130/3193/1450/1420/701/101/14
CoughRespiratory, thoracic and mediastinal disorders1/3136/3191/1450/1420/701/100/14
PruritusSkin and subcutaneous tissue disorders2/3131/3191/1452/1422/701/100/14

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Etoricoxib 60 mgEtoricoxib 90 mgNaproxen 1000 mgTotal
Mean45.4 ± 12.445.2 ± 11.344.5 ± 12.345.2 ± 12.2
Sex: Female, Male
Sex: Female, Male(Participants)Etoricoxib 60 mgEtoricoxib 90 mgNaproxen 1000 mgTotal
Female2094541295
Male493111116720
Spinal Pain Intensity
Spinal Pain Intensity(mm VAS)Etoricoxib 60 mgEtoricoxib 90 mgNaproxen 1000 mgTotal
Mean76.7 ± 14.276.7 ± 15.277.0 ± 14.076.8 ± 14.3
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Balazcs E, Sieper J, Bickham K, Mehta A, Frontera N, Stryszak P, Popmihajlov Z, Peloso PM. A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord. 2016 Oct 13;17(1):426. doi: 10.1186/s12891-016-1275-5. PubMed 27737664 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2010 to primary completion in Nov 2014, 49 months.

Results were first posted in Jul 2015, 7 months after primary completion.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 49 months is above that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2010
First posted
Sep 23, 2010
StartActual
Sep 27, 2010
Primary completionActual
Nov 12, 2014
CompletionActual
Nov 12, 2014
Results first posted
Jul 2, 2015
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01208207
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 23, 2010
Start date
Sep 27, 2010
Primary completion
Nov 12, 2014
Completion
Nov 12, 2014
Results posted
Jul 2, 2015
Last update
Jun 18, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Etoricoxib

Start the discussion